Barclays PLC Sells 37,149 Shares of Revvity Inc. $RVTY

Barclays PLC trimmed its stake in shares of Revvity Inc. (NYSE:RVTY) by 11.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 285,769 shares of the company’s stock after selling 37,149 shares during the period. Barclays PLC owned approximately 0.25% of Revvity worth $25,048,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RVTY. CYBER HORNET ETFs LLC bought a new stake in Revvity in the 2nd quarter worth approximately $32,000. MUFG Securities EMEA plc purchased a new stake in Revvity during the 2nd quarter valued at $34,000. Headlands Technologies LLC bought a new position in shares of Revvity during the 2nd quarter valued at $49,000. Smartleaf Asset Management LLC boosted its stake in shares of Revvity by 56.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock worth $58,000 after buying an additional 250 shares during the last quarter. Finally, Quent Capital LLC purchased a new position in shares of Revvity in the 3rd quarter worth $71,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

NYSE RVTY opened at $89.63 on Thursday. The company has a current ratio of 1.68, a quick ratio of 1.40 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 12 month low of $81.36 and a 12 month high of $118.30. The stock has a market cap of $10.02 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 1.92 and a beta of 1.10. The company’s 50 day moving average is $102.77 and its two-hundred day moving average is $96.63.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $772.06 million during the quarter, compared to analyst estimates of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.42 earnings per share. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. As a group, research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 8th. Investors of record on Friday, April 17th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity’s dividend payout ratio is currently 13.46%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RVTY. The Goldman Sachs Group began coverage on Revvity in a research report on Tuesday, December 9th. They set a “neutral” rating and a $105.00 price objective for the company. Wall Street Zen raised Revvity from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. JPMorgan Chase & Co. boosted their price target on Revvity from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Tuesday, February 3rd. Jefferies Financial Group upped their price target on shares of Revvity from $100.00 to $105.00 and gave the company a “hold” rating in a research report on Monday, February 2nd. Finally, Wells Fargo & Company increased their price objective on shares of Revvity from $107.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $113.67.

Revvity Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.